-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.鈥�
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
Epimax Ointment and Epimax Paraffin-Free Ointment can harm the eyes if used on the face. Do not prescribe these ointments for use on the face. Tell patients to wash their hands and avoid touching their eyes after using these鈥�
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
-
Healthcare professionals prescribing dupilumab should be alert to the risks of ocular reactions. New onset or worsening ocular symptoms require prompt review. Referral for ophthalmological examination should be made as appro鈥�
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
-
Following a review of the available toxicological data and a calculation of daily exposure to boron from a typical dosing regimen, we have concluded that the balance between the benefits and risks of chloramphenicol eye drop鈥�
-
A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.
-
A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.
-
Before initiating systemic vascular endothelial growth factor (VEGF) pathway inhibitors, carefully consider the risk of aneurysm and artery dissection in patients with risk factors. In patients who receive a systemic VEGF pa鈥�
-
Alerts were issued about T34 ambulatory syringe pumps, Gripper needles, and 1-day Acuvue Moist for astigmatism contact lenses.
-
Cases of pigmentary maculopathy leading to visual impairment have been reported with pentosan polysulfate, particularly after long-term use at high doses. Ensure patients taking pentosan polysulfate have regular ophthalmic e鈥�
-
A letter was sent to advise healthcare professionals about a restriction to the indication and route of administration for Mitomycin-C Kyowa 40 mg following the observation of increased sub-visible particles in the drug prod鈥�
-
Letters were sent about Oncaspar鈻� (pegaspargase), Ketalar (ketamine) injection, and Elmiron (pentosan polysulfate sodium). A recall was issued for several medicines taken out of the regulated medicines supply chain, includin鈥�
-
Letters were sent about Myocrisin (sodium aurothiomalate), Cerliponase alfa (Brineura鈻�), Darzalex鈻�(daratumumab), retinoids鈻�, and febuxostat (Adenuric). A recall alert was issued for medicines that were taken out of the regul鈥�
-
Letters were sent about alemtuzumab (Lemtrada), Selenase (sodium selenite pentahydrate), and Erelzi鈻� (etanercept).
-
Letters were sent about Xeljanz鈻� (tofacitinib), ranitidine, Nulojix (belatacept), fluoroquinolone antibiotics, Genvoya鈻�, Stribild鈻�, Tybost, and belimumab (Benlysta鈻�). Drug alerts were issued about Accord losartan potassium c鈥�
-
Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discont鈥�
-
In December 2018, a letter was sent to notify healthcare professionals of the discontinuation of Zovirax (Aciclovir) eye ointment. We also highlight the recent recall of Actavis batches of irbesartan/hydrochlorothiazide tabl鈥�
-
Letters were sent to healthcare professionals about Jext adrenaline autoinjectors, rivaroxaban, Ozurdex 700 micrograms intravitreal implant, sildenafil, hydrochlorothiazide, and Epilim Chronosphere (sodium valproate). We als鈥�
-
A supply disruption alert was issued by the Department of Health & Social Care (DHSC) on EpiPen and EpiPen Junior; see MHRA advice on extension of use beyond the expiry date for certain batches of EpiPen 300 microgram ad鈥�
-
Letters were sent about valproate medicines, atezolizumab (Tecentriq鈻�), and nusinersen (Spinraza鈻�). MHRA issued alerts and recalls for valsartan-containing medicines, Fiasp FlexTouch pre-filled pens, melatonin capsules, and 鈥�
-
Report to the Yellow Card Scheme suspected adverse reactions associated with medicines taken during pregnancy experienced by women or the baby or child. Obstetricians and midwives have a particularly important role in provid鈥�
-
An alert was issued about T34 ambulatory syringe pumps.
-
Central serous chorioretinopathy is a retinal disorder that has been linked to the systemic use of corticosteroids. Recently, it has also been reported after local administration of corticosteroids via inhaled and intranasal鈥�
-
Letters were sent about ibrutinib, daclizumab, aflibercept, valproate medicines, and arsenic trioxide.
-
Coadministration of a corticosteroid with an HIV-treatment-boosting agent may increase the risk of adrenal suppression due to a pharmacokinetic interaction.
-
In April 2016, letters were sent regarding canagliflozin (Invokana鈻�, Vokanamet鈻�), BCR-ABL tyrosine kinase inhibitors, pomalidomide (Imnovid鈻�), and retigabine (Trobalt)
-
Advise patients to tell their health professional if they experience severe eye irritation.
-
The new module helps clinicians understand how to identify, manage and avoid side effects when using corticosteroids.
-
Old pipette design withdrawn after reported eye injuries.
-
Cases of intraoperative floppy iris syndrome (IFIS) during cataract surgery have been reported in patients taking the atypical antipsychotics risperidone or paliperidone.
-
Reports of pigment changes in ocular tissue, skin, lips or nails.
-
Risk of intraocular lens opacification.
-
Healthcare professionals may have more responsibility to accurately prescribe an unlicensed medicine or an off-label medicine than when they prescribe a medicine within the terms of its licence.
-
To avoid the risk of air embolism, these products should not be infused under pressure.